Repligen Corporation (RGN)
XMUN 
Summary
RGN Chart
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen Q2 Earnings Call Highlights
Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted earnings outlook, citing continued order momentum and improved visibility into the second half.
Repligen Corporation (RGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Repligen Corporation ever had a stock split?
Repligen Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Olivier Loeillot CEO | XMUN Exchange | US7599161095 ISIN |
| US Country | 2,000 Employees | - Last Dividend | - Last Split | 26 Mar 1990 IPO Date |
Overview
Repligen Corporation is an innovative force in the biotechnological industry, primarily focusing on the development and commercialization of bioprocessing technologies and systems that play a crucial role in biological drug manufacturing. With a global reach that extends across North America, Europe, the Asia Pacific, and additional international markets, Repligen stands at the forefront of facilitating the production of biological drugs. The company, incorporated in 1981 and based in Waltham, Massachusetts, has established itself as a pivotal contributor to the biopharmaceutical and diagnostics sectors by offering a robust portfolio of products designed to enhance the efficiency and productivity of drug manufacturing processes. Through strategic collaboration agreements, such as with Navigo Proteins GmbH, Repligen continues to expand its technological arsenal, ensuring it remains synonymous with innovation and quality in the bioprocessing industry.
Products and Services
- Protein A Ligands and Cell Culture Growth Factor Products: They serve as the binding components of Protein A affinity chromatography resins, crucial for purifying biologics, alongside products designed to enhance cell culture growth, thereby increasing the yield of bioprocesses.
- Chromatography Products: This encompasses OPUS pre-packed chromatography columns for biologics purification, alongside smaller-scale columns used in process development, viral clearance, and process validation studies, reinforcing the versatility and efficiency of bioprocessing workflows.
- ELISA Test Kits and CaptivA Resins: These are essential for the detection and quantification of various biological agents, with chromatography resins under the CaptivA brand further supporting the purification stages of drug manufacturing.
- Filtration Products: The line includes XCell Alternating Tangential Flow systems for upstream perfusion and cell culture, TangenX cassettes, and KrosFlo systems for downstream processing like drug concentration and buffer exchange, alongside Spectra/Por dialysis products and ProConnex flow paths, showcasing a comprehensive range of solutions for biologic drug filtration needs.
- Process Analytics Products: With slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands, Repligen offers innovative solutions for process analytics, enabling more efficient and accurate monitoring and optimization of bioprocessing parameters.
